Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive leadership experience in raising capital, building biotech companies, and leading organizations to develop novel therapeutics. “Ambrx is at a key inflection point to advance our pipeline of Engineered Precision Biologics following our recent $200M private financing round. Gary’s strong track record of raising capital and building teams that support the development of breakthrough medicines is timely,” said Dr. Feng Tian, Chairman, President and CEO. “Gary’s expertise and leadership experience in finance, drug development, strategy, portfolio management, and operations uniquely position him to bring significant impact to our coming growth phases.” “I am passionate about working with companies that can change patients’ lives. Dr. Tian and his team have been the pioneers and innovators of the expanded genetic code technology using site-specific incorporation of synthetic amino acids into proteins to create drug candidates that are on the cusp of demonstrating the breakthrough nature of its platform. In particular, I am excited about ARX788’s recent Fast Track Designation by the FDA and its potential to be the best-in-class, next-generation, anti-HER2 ADC based on my experience of developing and commercializing HER2 products,” said Mr. Yeung. “I look forward to partnering with the management team and the board to grow the company and deliver novel Engineered Precision Biologics to patients.” Mr. Yeung joins Ambrx from Erasca, where he served as CFO & COO helping finance the company and advance several compounds into clinical trials. Prior to Erasca, Mr. Yeung helped build two biotech...

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU • Multiple Global Phase 2/3 Trials to Begin Early 2021 SAN DIEGO, December 10, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers. “As presented at the 2020 San Antonio Breast Cancer Symposium, ARX788 Phase 1 studies demonstrated promising antitumor activity in heavily pre-treated cancer patients at the recommended Phase 2 dose,” said Joy Yan, MD, PhD, Ambrx Chief Medical Officer. • ORR of 74% (14/19) and DCR of 100% in the 1.5 mg/kg cohort of the Phase 1 HER2-positive breast cancer trial in China • ORR of 67% (2/3) and DCR of 100% in the 1.5 mg/kg cohort of Phase 1 HER2-positive pan tumor trial in U.S. and Australia • mDOR or mPFS at the 1.5 mg/kg dose have not been reached. • ARX788 was well-tolerated, with most adverse events being mild or moderate, and were manageable. Patients who failed prior Kadcyla® (T-DM1) or Enhertu® (DS-8201a) achieved clinical responses, as assessed by RECIST v1.1 in the ACE-Pan Tumor-01 (ARX788-1711) trial, which enrolled patients with HER2 expressing cancers including breast cancer, gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, bladder, colorectal, biliary track, and salivary gland cancers in US and Australia. “The randomized controlled Phase 2/3 HER2-positive breast cancer pivotal trial in China has treated 22 subjects as of December 5th, 2020...

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed US$200 million crossover financing round. New investors include Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management. BofA Securities acted as the sole placement agent for the offering. “This financing represents our most significant capital raise to date and includes several leading global and US based healthcare funds. Since mid-2018, our new management team, set on a new long term vision, has committed to building company fundamentals and transforming Ambrx from a technology developer to a full-fledged biopharmaceutical company,” said Dr. Feng Tian, CEO and Chairman of Ambrx. “The conclusion of this financing and the strong data emerging from our ongoing clinical programs, as well as our deep preclinical pipeline of proprietary drug candidates, positions the company for rapid growth.” Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long acting therapeutic peptides for metabolic and cardiovascular disease. The company’s innovation engine continues to expand the clinical and preclinical pipeline by discovering new and valuable programs that take full advantage of the Ambrx technologies....

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties. SAN DIEGO, USA and BEIJING, China, January 12, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of next generation biologics using an expanded genetic code and Sino Biopharmaceutical Limited (1177.HK), a leading Chinese pharmaceutical company with a large number of medical products covering multiple therapeutic areas, announced a joint collaboration to develop two products enabled by Ambrx’s unique non-natural amino acid incorporation technology platforms. Under the agreement, Ambrx received an upfront payment to create two innovative drug candidates, with Sino Biopharma then leading IND enabling activities for both China and the US. The parties will jointly develop the programs to world-class standards with Sino Biopharma commercializing the products within the greater China area and Ambrx commercializing the products rest-of-world. Ambrx is eligible to receive additional milestone payments for development, regulatory, and sales-based events, as well as tiered royalties on future sales. “We are delighted to join forces with Ambrx, a leader in precision engineered biologics and breakthrough protein therapeutics, to develop two next generation cancer drugs” commented Stephen Hsin Tse, Executive Director of Sino Biopharma. “This collaboration helps fulfill our strong commitment to develop and commercialize innovative biological drugs for the China market.” The collaboration combines Ambrx’s clinically validated ReCODE™ and EuCODE™ platforms with Sino Biopharma’s strong resources and commitment to bring nextgeneration biologic drugs to market. “Sino Biopharma is a large, unique and fast-growing powerhouse in the Chinese pharmaceutical industry, combining strong drug development expertise with substantial commercial...